Cannabis terpenes cut chronic pain without the high
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- University of Arizona Health Sciences researchers tested four cannabis terpenes—geraniol, linalool, beta-caryophyllene, and alpha-humulene—and found all four significantly reduced pain in mouse models of fibromyalgia and post-surgical pain
- Geraniol delivered the strongest pain-relieving effects, followed by linalool, beta-caryophyllene, and alpha-humulene
- Unlike THC, terpenes produce no psychoactive effects, making them an appealing candidate for pain treatment
- The compounds failed to relieve acute pain from injuries like burns or stubbed toes, but worked for chronic and pathological pain conditions
- The pain relief worked through the adenosine A2a receptor—the same receptor caffeine targets and blocks—suggesting terpenes may have sedative properties that warrant further study
- Fibromyalgia affects up to 5% of the global population and roughly 4 million US adults, with limited effective treatment options currently available
- Published in Pharmacological Reports and funded by the NIH, the study points to a potential non-opioid alternative for the ~310 million major surgeries performed worldwide each year
Why it matters: Terpenes offer a non-psychoactive alternative to opioids for the roughly 310 million major surgeries performed yearly and for fibromyalgia, which affects about 4 million US adults with few effective treatments. The catch: results are from mouse models, so human trials are the necessary next step before any clinical use.
